{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022325","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.797712+00:00","generated_at":"2026-05-16T20:21:44.157885+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers","bullets":["Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.","Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.","Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.","Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.","Hired Philip Stocton as Senior Director of Sales and added two regional sales managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022325","json":"https://secwatch.observer/filing/0001493152-25-022325.json","markdown":"https://secwatch.observer/filing/0001493152-25-022325.md","text":"https://secwatch.observer/filing/0001493152-25-022325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/0001493152-25-022325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:21:44.157885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}